Fig. 2.
Determination of residual cell viability and colony forming ability of SK-N-DZ and SK-N-BE2 cells after treatments. (A) MTT assay for determination of residual cell viability. Treatments: control (CTL), scrambled miR-138 mimic (50 nM) for 12 h, hTERT shRNA plasmid (1 μg/ml) for 12 h, miR-138 mimic (50 nM) for 12 h, 100 μM APG for 24 h, hTERT shRNA plasmid (1 μg/ml) for 12 h + 100 μM APG for 24 h, and miR-138 mimic (50 nM) for 12 h + 100 μM APG for 24 h. (B) Clonogenic assay for evaluation of cell survival and proliferation. Treatments: CTL, scrambled miR-138 mimic (50 nM) for 12 h, miR-138 mimic (50 nM) for 12 h, hTERT shRNA plasmid (1 μg/ml) for 12 h + 100 μM APG for 24 h, and miR-138 mimic (50 nM) for 12 h + 100 μM APG for 24 h. Then, cells were harvested, 200 cells were seeded in 6-well plates, allowed to attach for 5 h, and again treated similarly with scrambled miR-138 mimic, miR-138 mimic, hTERT shRNA plasmid, and APG as described above. Difference between CTL or scrambled miR-138 and a monotherapy or a combination therapy was considered significant at *p < 0.05 or **p < 0.01.